Patents by Inventor Jiquan Zhang

Jiquan Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20230220090
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Application
    Filed: December 30, 2022
    Publication date: July 13, 2023
    Inventors: Jennifer Brogdon, Saar Gill, David Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • Treatment of cancer using a CD123 chimeric antigen receptor
    Patent number: 11591404
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: February 28, 2023
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Saar Gill, David Jonathan Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • PHOSPHOGLYCERATE KINASE 1 (PGK) PROMOTERS AND METHODS OF USE FOR EXPRESSING CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20230052970
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.
    Type: Application
    Filed: October 3, 2022
    Publication date: February 16, 2023
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, David Glass, Thomas Huber, Julia Jascur, Carl H. June, Jihyun Lee, Joan Mannick, Michael C. Milone, Leon Murphy, Avery D. Posey, Huijuan Song, Yongqiang Wang, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • BINDING MOLECULES AGAINST CD3 AND USES THEREOF
    Publication number: 20230037682
    Abstract: Provided are CD3 binding molecules that specifically bind to CD3, for example monospecific binding molecules that specifically bind to CD3 and multispecific binding molecules (MBMs) that specifically bind to CD3 and a tumor-associated antigen, conjugates comprising the CD3 binding molecules, and pharmaceutical compositions comprising the CD3 binding molecules and conjugates. Provided are methods of using the CD3 binding molecules, conjugates, and pharmaceutical compositions to activate T cells in a subject, for example a subject having a cancer or autoimmune disease. Provided are recombinant host cells engineered to express the CD3 binding molecules and methods of producing the CD3 binding molecules by culturing the host cells under conditions in which the CD3 binding molecules are expressed.
    Type: Application
    Filed: December 4, 2019
    Publication date: February 9, 2023
    Inventors: Brian Walter GRANDA, Daniel LENHERR-FREY, Xuerui LUO, Amy RAYO, Fei ZHANG, Jiquan ZHANG
  • Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
    Patent number: 11459390
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: October 4, 2022
    Assignees: Novartis AG, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, David Glass, Thomas Huber, Julia Jascur, Carl H. June, Jihyun Lee, Joan Mannick, Michael C. Milone, Leon Murphy, Avery D. Posey, Huijuan Song, Yongqiang Wang, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • MULTISPECIFIC MOLECULES TARGETING CLL-1
    Publication number: 20210198368
    Abstract: The present invention is directed to multispecific/multivalent molecules comprising an anti-CLL-1 binding domain.
    Type: Application
    Filed: January 20, 2017
    Publication date: July 1, 2021
    Inventors: Michael DALEY, Hilmar EBERSBACH, Julia JASCUR, Qilong WU, Qiumei YANG, Jiquan ZHANG
  • TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20210139595
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
    Type: Application
    Filed: October 28, 2020
    Publication date: May 13, 2021
    Inventors: Hilmar Erhard Ebersbach, Thomas Huber, Julia Jascur, Celeste Richardson, Reshma Singh, Huijuan Song, Qilong Wu, Jiquan Zhang
  • TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20210002377
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Application
    Filed: May 27, 2020
    Publication date: January 7, 2021
    Inventors: Jennifer Brogdon, Saar Gill, David Jonathan Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • Treatment of cancer using a CD33 chimeric antigen receptor
    Patent number: 10851166
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: December 1, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Hilmar Erhard Ebersbach, Thomas Huber, Julia Jascur, Celeste Richardson, Reshma Singh, Huijuan Song, Qilong Wu, Jiquan Zhang
  • TREATMENT OF CANCER USING A CLL-1 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20200215171
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
    Type: Application
    Filed: December 27, 2019
    Publication date: July 9, 2020
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Jonathan Glass, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • Treatment of cancer using a CD123 chimeric antigen receptor
    Patent number: 10703819
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: July 7, 2020
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Jennifer Brogdon, Saar Gill, David Jonathan Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • Treatment of cancer using a CLL-1 chimeric antigen receptor
    Patent number: 10568947
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: February 25, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Glass, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20180312595
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Application
    Filed: October 6, 2017
    Publication date: November 1, 2018
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Saar Gill, David Jonathan Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • PHOSPHOGLYCERATE KINASE 1 (PGK) PROMOTERS AND METHODS OF USE FOR EXPRESSING CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20180118834
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.
    Type: Application
    Filed: January 15, 2016
    Publication date: May 3, 2018
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, David Glass, Thomas Huber, Julia Jascur, Carl H. June, Jihyun Lee, Joan Mannick, Michael C. Milone, Leon Murphy, Avery D. Posey, Huijuan Song, Yongqiang Wang, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20180044423
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
    Type: Application
    Filed: August 29, 2017
    Publication date: February 15, 2018
    Inventors: Hilmar Erhard Ebersbach, Thomas Huber, Julia Jascur, Celeste Richardson, Reshma Singh, Huijuan Song, Qilong Wu, Jiquan Zhang
  • Treatment of cancer using a CD123 chimeric antigen receptor
    Patent number: 9815901
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: November 14, 2017
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Saar Gill, David Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • Treatment of cancer using a CD33 chimeric antigen receptor
    Patent number: 9777061
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: October 3, 2017
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Hilmar Erhard Ebersbach, Thomas Huber, Julia Jascur, Celeste Richardson, Reshma Singh, Huijuan Song, Qilong Wu, Jiquan Zhang
  • TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20160096892
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
    Type: Application
    Filed: July 21, 2015
    Publication date: April 7, 2016
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NOVARTIS AG
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Glass, Thomas Huber, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Huijuan Song, Qilong Wu, Jiquan Zhang
  • TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20160068601
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Application
    Filed: August 19, 2015
    Publication date: March 10, 2016
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NOVARTIS AG
    Inventors: Jennifer Brogdon, Saar Gill, David Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • TREATMENT OF CANCER USING A CLL-1 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20160051651
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
    Type: Application
    Filed: July 21, 2015
    Publication date: February 25, 2016
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NOVARTIS AG
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Glass, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang